Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of TRAIL-R1,TNFRSF10A. The page also collects GeneMedi's different modalities and formats products for TRAIL-R1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TRAIL-R1 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. [provided by RefSeq, Jul 2008]

Target IDGM-T77645
Target NameTRAIL-R1
Gene ID8797
Gene Official NameTNFRSF10A
Gene AliasAPO2, CD261, DR4, TRAILR-1, TRAILR1
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target


Pre-made TRAIL-R1-specific INN-index biosimilar (antibody&conjugates)-mapatumumab

Anti-TRAIL-R1 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-INN-905Pre-Made Mapatumumab Biosimilar, Whole Mab, Anti-TNFRSF10A/TRAIL-R1 Antibody: Anti-APO2/CD261/DR4/TRAILR-1/TRAILR1 therapeutic antibodymapatumumabTNFRSF10A/TRAIL-R1Whole  mAbINN mab



Pre-made anti-TRAIL-R1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-TRAIL-R1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRAIL-R1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T77645-AbAnti-TRAIL-R1/TNFRSF10A monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibody, Cytokine antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×